Catalent Inc
NYSE:CTLT
Catalent Inc
Cash Equivalents
Catalent Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Catalent Inc
NYSE:CTLT
|
Cash Equivalents
$162m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
11%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$3.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$719m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Catalent Inc's Cash Equivalents?
Cash Equivalents
162m
USD
Based on the financial report for Mar 31, 2024, Catalent Inc's Cash Equivalents amounts to 162m USD.
What is Catalent Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
11%
Over the last year, the Cash Equivalents growth was -36%. The average annual Cash Equivalents growth rates for Catalent Inc have been -45% over the past three years , -7% over the past five years , and 11% over the past ten years .